MDL | - |
---|---|
Molecular Weight | 338.51 |
Molecular Formula | C18H30N2O2S |
SMILES | O=S(C1=CC=CC(C)=C1)(N(C)[C@H](C)CCN2CCC(C)CC2)=O |
SB 258719 is a selective 5-HT 7 receptor antagonist with high affinity ( pK i =7.5) for the receptor. SB 258719 can be used for the research of cancer and neurological disease [1] [2] [3] .
5-HT 7 Receptor 7.5 (pKi) |
SB 258719 (1, 3 and 10 μM; HEK 293 cells) produces a concentration-related rightward-shift of the 5-CT concentration-response curve with no signifcant alteration in the maximal response to 5-CT [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
SB 258719 (5-20 mg/kg; i.p.) significantly attenuates the 5-CT-induced hypothermia [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: | Male Swiss Webster mice (20-25 g) [2] . |
Dosage: | 5-20 mg/kg |
Administration: | I.p. |
Result: | Significantly attenuated the 5-CT-induced hypothermia. |
Liquid
Room temperature in continental US; may vary elsewhere.
Pure form | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
DMSO : 250 mg/mL ( 738.53 mM ; Need ultrasonic)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 2.9541 mL | 14.7706 mL | 29.5412 mL |
5 mM | 0.5908 mL | 2.9541 mL | 5.9082 mL |
10 mM | 0.2954 mL | 1.4771 mL | 2.9541 mL |